Resverlogix Commences Phase 2 Atherosclerosis Clinical Trial

Calgary, Canada (ots/PRNewswire) - Resverlogix Corp.
("Resverlogix" or the "Company") announced today that it has begun
dosing patients in its US Phase 2 clinical trial lead by Cleveland
Clinic. This trial will examine RVX-208, Resverlogix's oral small
molecule therapy for the treatment of atherosclerosis, in patients
with stable coronary artery disease (CAD). This study is chaired by
Dr. Steven Nissen, MD, Chairman of the Cleveland Clinic Department of
Cardiovascular Medicine and the principal investigator is Dr. Stephen
Nicholls, Medical Director of Intravascular Ultrasound at Cleveland
Clinic. The Cleveland Clinic has named this trial, ASSERT, which
stands for ApoA1 Synthesis Stimulation Evaluation in Patients
Requiring Treatment for Coronary Artery Disease. A total of 40
investigator sites across the US will be participating in the study.

"I am pleased to see the start of this 18 week randomized,
outpatient multicenter, double-blind, placebo-controlled study that
will administer RVX-208 to approximately 280 patients with stable CAD
for 13 weeks," said Dr. Stephen J. Nicholls, MBBS, PhD, Medical
Director of the Atherosclerosis Imaging Core Laboratories at
Cleveland Clinic and Cardiovascular Director of the Cleveland Clinic
Coordinating Center for Clinical Research. "This trial is one of two
parallel studies, in this particular study the focus is on stable
CAD patients, while the second trial will be focused on unstable
acute coronary syndrome and will include the use of intravascular
ultrasound (IVUS)."

Cardiovascular disease is the leading cause of death in the US
and other developed nations costing the American health care system
an estimated $448.5 billion in 2008. A key underlying cause of
cardiovascular disease is atherosclerosis, a build-up of plaque in
the arteries often referred to as 'hardening of the arteries'.

The primary objective of this study is to determine if RVX-208
will produce an increase in plasma ApoA-l levels compared to placebo
group after three months of dosing. The secondary objectives are to
examine the safety and tolerability of RVX-208, to compare the dose
and time response relationships for ApoA-l over time as well as to
examine and key reverse cholesterol makers such as Alpha 1 HDL.

"The initiation of the ASSERT Trial is another important
milestone that Resverlogix has achieved this year. Our clinical
trials to date have produced very encouraging results for our lead
drug, RVX-208, for the treatment of atherosclerosis. Currently, there
is a void in therapies that can regress atherosclerosis. The current
standard of care is statin therapies, which can only stop
atherosclerosis from progressing but in almost all cases is unable to
remove it. If RVX-208 is able to achieve this goal it would be an
important step toward the reduction of disease risk and lower health
system costs. We are delighted to have this trial dose its first
patients two months ahead of schedule," said Donald J. McCaffrey,
President and CEO of Resverlogix.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates
endogenous ApoA-I production, is positioned to be one of the most
promising emerging drugs in the treatment of atherosclerosis. To the
Company's knowledge RVX-208 is the only novel small molecule that is
specifically designed to increase ApoA-I production and thereby raise
HDL levels thus enhancing HDL functionality to augment reverse
cholesterol transport (RCT). RCT is a pathway by which accumulated
cholesterol is transported from the arterial wall to the liver for
excretion, thus preventing atherosclerosis.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in
the development of novel therapies for important global medical
markets with significant unmet medical needs. The NexVas(TM) PR
program is the Company's primary focus which is to develop novel
small molecules that enhance ApoA-I. These vital therapies address
the burden of atherosclerosis and other important diseases such as
Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral
Artery Disease and other vascular disorders. Resverlogix Corp. trades
on the Toronto Stock Exchange . For further information please visit
http://www.resverlogix.com.

This news release may contain certain forward-looking statements
as defined under applicable Canadian securities legislation,
including our statements with respect to vision to be a leader in the
research, development and commercialization of novel therapeutics
that reduce the risk of cardiovascular disease including
atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery
Disease and other vascular diseases. These forward-looking statements
contained herein that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking
statements. We can give no assurance that any of the events or
expectations will occur or be realized. By their nature,
forward-looking statements are subject to numerous known and unknown
risks and uncertainties including but not limited to those
associated with the success of research and development programs,
clinical trial programs including possible delays in patient
recruitment, the regulatory approval process, competition, securing
and maintaining corporate alliances, market acceptance of the
Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of
intellectual property, financing capability, the potential dilutive
effects of any financing, reliance on subcontractors and key
personnel and additional risk factors discussed in other documents we
file from time to time with securities authorities, which are
available through SEDAR at http://www.sedar.com. Additionally, risks
and uncertainties are discussed in detail in the December 15, 2009
MD&A. The forward-looking statements contained in this news release
are expressly qualified by this cautionary statement are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. The TSX Exchange does not
accept responsibility for the adequacy or accuracy of this news
release.

For further information: Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: +1-(403)254-9252, Fax:
+1-(403)-256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone:
+1-(403)-254-9252, Fax: +1-(403)-256-8495, Email:
Sarah@resverlogix.com; US Investor Relations, Susan Noonan, Managing
Partner, S.A. Noonan Communications, LLC, Phone: +1-(212)-966-3650,
Email: susan@sanoonan.com; US Media Relations, Eric Goldman, Vice
President, Rx Communications Group, Phone: +1-(917)-322-2563, Email:
egoldman@rxir.com

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: Theresa Kennedy, VP,
CorporateCommunications, Resverlogix Corp., Phone: +1-(403)254-9252,
Fax:+1-(403)-256-8495, Email: Theresa@resverlogix.com; Sarah
Zapotichny,Manager, Investor Relations, Resverlogix Corp., Phone:
+1-(403)-254-9252,Fax: +1-(403)-256-8495, Email:
Sarah@resverlogix.com; US InvestorRelations, Susan Noonan, Managing
Partner, S.A. Noonan Communications, LLC,Phone: +1-(212)-966-3650,
Email:susan@sanoonan.com; US Media Relations, Eric Goldman, Vice
President, RxCommunications Group, Phone: +1-(917)-322-2563, Email:
egoldman@rxir.com